Whole-genome sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors
The Oncologist · 07.10.2026 · 31 (11)
DOI: 10.1093/oncolo/oyag404 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 16.10.2026. Verfasst von Mridula George und 37 weiteren Autor:innen. Beteiligte Einrichtung: Breast Cancer Center, Rutgers Cancer Institute, New Brunswick, NJ 08901, United States. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Whole Genome Sequencing, Neoplasm Recurrence, Local, Biomarkers, Tumor. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Circulating tumor DNA (ctDNA) assays can transform patient management by enabling molecular residual disease (MRD) detection, prognosis prediction, and treatment monitoring. Here, we report clinical performance of Signatera Genome, a whole-genome sequencing (WGS)-based ctDNA assay, in a diverse pan-cancer cohort at landmark and longitudinal settings post-definitive treatment.
Methods
We performed a retrospective analysis of 386 patients with one of the following cancers: breast, colorectal, non-small-cell lung, melanoma, or renal cell carcinoma. Signatera Genome assays, designed with high-quality variants selected from the matched tumor and normal WGS data, were used to detect ctDNA in the associated patients’ longitudinal plasma samples collected post-operatively. The correlation between ctDNA-based MRD status and systemic, distant recurrence-free survival (systemic DRFS) was assessed using Cox regression analysis.
Results
In the pan-cancer cohort, landmark analysis at 3 months post-surgery revealed that patients with MRD-positivity had significantly inferior systemic DRFS compared to ctDNA-negative patients (hazard ratio [HR]: 23.7, P < .0001). Additionally, ∼30% improvement in 24-month systemic DRFS was observed among adjuvant-treated MRD-positive patients, whereas MRD-negative patients derived no clear benefit from adjuvant therapy. In the longitudinal setting, MRD positivity anytime post-definitive treatment surveillance significantly correlated with shorter systemic DRFS compared to serial MRD negativity (HR: 103.4, P < .0001). Tumor-specific analyses yielded similar findings. Notably, 62% (72/116) of patients had ctDNA detected in the ultra-sensitive range of <100 ppm.
Conclusions
Our findings underscore the robust clinical performance of the Signatera Genome assay for MRD detection across solid tumors. Its broad applicability and high specificity support its integration into clinical practice and prospective trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Breast Cancer Center, Rutgers Cancer Institute, New Brunswick, NJ 08901, United States.
- Department of Thoracic Surgery & Lung Transplantation, Baylor University Medical Center, Dallas, TX 75246, United States.
- Hematology and Medical Oncology, Advent Health Cancer Institute, Altamonte Springs, Orlando, FL 32804, United States.
- Urologic Oncology, UT Southwestern Medical Center, Dallas, TX 75235, United States.
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan.
- Division of Oncology, Washington University School of Medicine in St. Louis, St Louise, MO 63110, United States.
ORCID-Profile: Mridula George, Gary S Schwartz, Wassim McHayleh, Hideaki Bando, Takayuki Yoshino, Arkarachai Fungtammasan, Bharat Sridhar, Himanshu Sethi, Morgan M Quail, Sharlene Velichko, Alexander Hsieh, Carcia Carson, Meenakshi Malhotra, Matthew Rabinowitz, Ryan K Swenerton, Adham Jurdi, Adam C ElNaggar, Michael Krainock, Caitlin A Schonewolf, Angel A Rodriguez, Minetta C Liu, Matthew D Galsky
Zitieren
APA
George, M., Schwartz, G. S., McHayleh, W., Margulis, V., Bando, H., Yoshino, T., Ansstas, G., Scalise, C. B., Sudhaman, S., Fungtammasan, A., Sridhar, B., Feeney, J., Sethi, H., Quail, M. M., Velichko, S., Tan, W., Hsieh, A., Butskova, A., Ptashkin, R., …, & Galsky, M. D. (2026). Whole-genome sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors. The Oncologist, 31(11). https://doi.org/10.1093/oncolo/oyag404
Vancouver
George M, Schwartz GS, McHayleh W, Margulis V, Bando H, Yoshino T, et al. Whole-genome sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors. The Oncologist. 2026;31(11). doi:10.1093/oncolo/oyag404
BibTeX
@article{George2026,
author = {George, Mridula and Schwartz, Gary S and McHayleh, Wassim and Margulis, Vitaly and Bando, Hideaki and Yoshino, Takayuki and Ansstas, George and Scalise, Carly Bess and Sudhaman, Sumedha and Fungtammasan, Arkarachai and Sridhar, Bharat and Feeney, Jordan and Sethi, Himanshu and Quail, Morgan M and Velichko, Sharlene and Tan, Wilson and Hsieh, Alexander and Butskova, Anastasia and Ptashkin, Ryan and Carson, Carcia and Wray, Ashley and Palsuledesai, Charuta C and Malhotra, Meenakshi and Zehir, Ahmet and Kirkizlar, Eser and Rabinowitz, Matthew and Swenerton, Ryan K and Heilek, Gabrielle and Jurdi, Adham and ElNaggar, Adam C and Krainock, Michael and Schonewolf, Caitlin A and Rodriguez, Angel A and Sharma, Shruti and Kalashnikova, Ekaterina and Liu, Minetta C and Aleshin, Alexey and Galsky, Matthew D},
title = {Whole-genome sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {11},
doi = {10.1093/oncolo/oyag404}
}
EUVIMED